Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
06/12/2022 12:43
Dec 6 (Reuters) - Tetra Bio Pharma Inc TBP.TO :
* TETRA BIO-PHARMA ANNOUNCES RESULTS OF ARTIFICIAL
INTELLIGENCE
STUDY OF ARDS-003 COMBINED WITH FAVIPIRAVIR
* TETRA BIO PHARMA INC - TETRA AND CELLVERA TO DEVELOP AN
ORALLY
ADMINISTERED TREATMENT, ARDS-003, IN COMBINATION WITH
FAVIPIRAVIR
* TETRA BIO PHARMA INC - RESULTS FROM TRIAL SHOWS
FAVIPIRAVIR MAY
IMPROVE SEVERE COVID-19 RECOVERY AND VENTILATOR-FREE SURVIVAL IN
YOUNGER PATIENTS
Source text for Eikon: ID:nPn5FdvQGa
Further company coverage: TBP.TO
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding